Back to today’s briefing

Story perspectives

Intellia's CRISPR Therapy Cuts HAE Attacks 87% in Phase 3

4/28/2026

45 3 Full Breakdown

Summary

Story summary

Intellia Therapeutics said its CRISPR therapy lonvoguran ziclumeran (lonvo-z) cut hereditary angioedema attacks by 87% in a Phase 3 trial.
In the 80-patient HAELO study, 52 received lonvo-z and 28 placebo, with 62% of treated patients staying attack-free versus 11% on placebo and mild-moderate side effects.
Intellia has begun a biologics license application with the FDA and plans a U.S. launch in early 2027, with price above Dawnzera and Takhzyro.

1 of 1

Story summary

Intellia Therapeutics said its CRISPR therapy lonvoguran ziclumeran (lonvo-z) cut hereditary angioedema attacks by 87% in a Phase 3 trial.
In the 80-patient HAELO study, 52 received lonvo-z and 28 placebo, with 62% of treated patients staying attack-free versus 11% on placebo and mild-moderate side effects.
Intellia has begun a biologics license application with the FDA and plans a U.S. launch in early 2027, with price above Dawnzera and Takhzyro.